-The Economic Times Drug companies paid as little as 50,000 as compensation to families of volunteers who died during clinical trials for new medicines last year, leading to sharp criticism about the paltry sums being handed out and growing clamour among health groups for more stringent guidelines on new drug trials.  According to government data accessed by a healthcare activist through an RTI query, Germany's Fresenius Kabi paid 50,000 each to the...

-The Indian Express Government must bring the assisted reproductive technologies bill to Parliament. More stringent regulation could have saved lives Sushma Pandey, just 17 years old, reportedly died due to procedures related to egg harvesting conducted on her by a fertility clinic in Mumbai. Two years after her death, the Bombay high court did well to criticise the police for not prosecuting the hospital for its flagrant violation of the age requirement...

-The Hindu Growing demand for male children, ‘same-caste’ surrogates   Unregulated fertility clinics indulge in medical malpractices, including physical and economical exploitation of women, a study has shown. Shockingly, preference for male children and demand for ‘same caste’ surrogates are prevalent in India. “Some couples, say about 5 per cent, who come to my clinic demand surrogates from their own caste,” says Nayna Patel, of the Akanksha Fertility Clinic in Anand, Gujarat that has come...

-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...

-The Indian Express India may not be a testing hub for Big Pharma. But informed consent must be non-negotiable Figures released by the World Health Organisation, which show that 10 Indian subjects of clinical field trials die every week, have rekindled concerns that this country has become a testing hub for Big Pharma. Ironically, the same figures deflate this persistent fear, revealing that only 1.5 per cent of global trials have been...